Nuvectis Pharma, INC 10-Q quarterly reports

Nuvectis Pharma, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development, significant operating losses, and a substantial capital raise in July 2026.

Nuvectis Pharma reported its Q1 2026 results, showing continued operating losses and net losses, with cash reserves sufficient for at least 12 months, while advancing its NXP900 clinical development.

Nuvectis Pharma reported increased losses in Q3 2025, driven by higher R&D and G&A expenses, while advancing its NXP900 clinical program and discontinuing NXP800 development in ovarian cancer.

Nuvectis Pharma reported increased net losses in Q2 2025 due to higher research and development and general and administrative expenses, despite a significant capital raise.

Nuvectis Pharma reports its Q1 2025 financial results, emphasizing ongoing clinical development of NXP800 and NXP900 and its current cash position.

Nuvectis Pharma, a biopharmaceutical company, released its financial results for the third quarter of 2024, highlighting ongoing clinical development of its precision medicine candidates.

Nuvectis Pharma, a biopharmaceutical company, reported its financial results for the second quarter of 2024, highlighting ongoing clinical trials and financial activities.

Nuvectis Pharma reports a net loss of $4.171 million for the first quarter of 2024, while continuing to advance its clinical programs and raise capital through its at-the-market offering.